Finance built for long cycles, milestone funding, and gross-to-net reality.
Pharma and life-sciences companies burn cash for years before revenue, raise against clinical and regulatory milestones, and live with gross-to-net deductions that distort headline sales. We bring the cash discipline, runway modeling, and investor reporting that long-horizon science businesses need.
The US pharmaceutical market by the numbers.
The financial complexity science companies cannot run on a spreadsheet.
Pharma economics do not look like a normal operating business. The finance function has to model years of burn, fund against milestones, and translate scientific risk into numbers an investor or board can act on.
Years of burn before a dollar of revenue.
A milestone-linked burn and runway model tells you exactly when the next raise must close — before the lab does.
Funding tied to clinical and regulatory milestones.
We model each tranche against its trigger so the cash plan and the science plan move together.
Gross-to-net deductions distort headline sales.
A gross-to-net bridge with documented accrual assumptions makes revenue defensible to auditors and investors.
Non-dilutive funding is on the table but unmanaged.
We track grant budgets and milestones so non-dilutive capital extends runway instead of creating audit risk.
Investors and boards want science translated into numbers.
A monthly board pack and scenario model gives the board confidence without pulling the founder out of the lab.
Pharma finance questions founders ask.
Do you work with pre-revenue, clinical-stage companies?
Can you handle gross-to-net once a product is commercial?
How do you model milestone-based fundraising?
Do you support grant and non-dilutive funding reporting?
Bring CFO-level clarity to your Pharma & Life Sciences business.
Book a free 30-minute clarity call. We map your finance function and tell you exactly what is worth fixing first.